Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 12/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.36 |
| ▸ | SELP | P16109 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136535 | 0.93 | TLR4 (0.70) | TLR4SELP | |
| SCHEMBL12836658 | 0.91 | TLR4 (0.58) | TLR4LPAR1CNR1CNR2TRPV1 | |
| SCHEMBL12836667 | 0.89 | TLR4 (0.76) | TLR4LY96 | |
| SCHEMBL13286608 | 0.89 | TLR4 (0.76) | TLR4LY96 | |
| SCHEMBL13302898 | 0.89 | TLR4 (0.76) | TLR4LY96 | |
| SCHEMBL17471186 | 0.85 | TLR4 (0.60) | TLR4CNR1CNR2TRPV1LY96 | |
| SCHEMBL15292202 | 0.85 | TLR4 (0.60) | TLR4CNR1CNR2TRPV1LY96 | |
| SCHEMBL13325121 | 0.85 | TLR4 (0.65) | TLR4LY96 | |
| SCHEMBL13803955 | 0.85 | TLR4 (0.65) | TLR4LY96 | |
| SCHEMBL12601161 | 0.85 | TLR4 (0.65) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207144-B2 | Improves the stability over time of a corresponding tetrasodium salt useful as a preventive or therapeutic for septicemia, endotoxemia or improving prognosis following coronary artery bypass surgery | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20080227991-A1 | Sodium salt of disaccharide compound, production method and use of same | EISAI R&D MANAGEMENT CO., LTD. | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227991-A1 | Sodium salt of disaccharide compound, production method and use of same | MAN2A1, MAN2B2, MAN2B1 | TLR4 557/4885LPAR1 1020/4885CNR1 1532/4885 |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | MAN2B2, MAN2A1, MAN2B1 | TLR4 1500/4885LPAR1 2295/4885CNR1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.